Electrochemotherapy of superficial tumors – Current status:

Campana, Luca Giovanni; Miklavčič, Damijan; Bertino, Giulia; Marconato, R; Valpione, Sara; Imarisio, Ilaria; Dieci, Maria Vittoria; Granziera, Elisa; Čemažar, Maja; Alaibac, Mauro; Serša, Gregor

doi:10.1053/j.seminoncol.2019.04.002

Cited by 87 publications

(59 citation statements)

References 252 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After the electric field is applied, a cell membrane permeabilization is produced by a physical phenomenon known as electroporation, affecting all tumor cells, regardless of the histological tissue. 11 A meta-analysis of ECT clinical studies in human oncology showed that the overall objective response (OR) rate varies from 62.6% to 82.2% depending also on which route was used to administer the drug. 12 Great efforts are being made to extend ECT to non-cutaneous locations such as liver 13 , brain 14 , and bones.…”

Section: Introductionmentioning

confidence: 99%

Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome

Tellado

Maglietti

Michinski

et al. 2020

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundOral malignant melanoma is the most common, but aggressive oral cancer in dogs with poor prognosis. Electrochemotherapy (ECT) has therapeutic potential in such tumors as effective local treatment. Therefore, the aim of this prospective clinical study was to evaluate treatment effectiveness of ECT in as first line treatment for canine oral malignant melanoma, and search for factors influencing treatment outcome.MethodsSixty-seven canines with primary oral malignant melanoma, non-candidates for first-line therapy, were enrolled. All dogs received ECT and follow-up exams for the span of two years.ResultsBased on RECIST criteria, the objective response rate was 100%, 89.5%, 57.7%, and 36.4%, in stage I, II, III and IV, respectively. Only patients in stage I, II and III with partial or complete response improved their quality of life. The median time to progression was 11, 7, 4 and 4 months, and median survival time after the treatment was 16.5, 9.0, 7.5 and 4.5 months, for patients in stage I, II, III and IV, respectively. Significantly better was local response in stage I and II disease (p = 0.0013), without the bone involvement (p = 0.043)ConclusionsElectrochemotherapy is effective local treatment of oral canine malignant melanoma when no alternative treatment is available. Better response is expected in stage I and II patients with tumors without bone involvement.

show abstract

Section: Introductionmentioning

confidence: 99%

Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome

Tellado

Maglietti

Michinski

et al. 2020

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…One of the antitumor mechanisms of ECT involves immune response, provoked by immunogenic cell death and enhanced tumor antigen expression. 5 This might be especially important in the treatment of BCCs since these tumors have the greatest mutational burden among all human cancers. 15 Consequently, numerous tumor antigens provoke immune system, which is the most probable reason for the less aggressive nature of BCCs.…”

Section: Discussionmentioning

confidence: 99%

“…The third mechanism involves immune response provoked by immunogenic cell death and enhanced tumor antigen expression. 5 In the ECT treatment of non-melanoma skin cancer (NMSC) compelling results were achieved when using standard dose (15,000 IU/m 2 ) of intravenously administrated BLM. 6 According to published BLM pharmacokinetics study, an equally good antitumor response might be obtained with a reduced dose of BLM in the elderly population due to the slow elimination rate of BLM.…”

Section: Introductionmentioning

confidence: 99%

Long term response of electrochemotherapy with reduced dose of bleomycin in elderly patients with head and neck non-melanoma skin cancer

Jamsek

Serša

Bošnjak

et al. 2020

Radiology and Oncology

Self Cite

View full text Add to dashboard Cite

BackgroundElectrochemotherapy (ECT) is a local cancer treatment based on electroporation where the electric field is used to enhance cell membrane permeability and thereby facilitating the transition of chemotherapeutic agents into the cell. For the treatment of non-melanoma skin cancer, a standard dosage of 15,000 IU/m2 bleomycin (BLM) is used. The aim of the present study was to evaluate the long-term ECT response in the group of elderly patients with non-melanoma skin cancer treated with a reduced dose of BLM in comparison to the outcome in the patients treated with the standard dose of BLM.Patients and methodsTwenty-eight patients older than 65 years, with a total of 52 non-melanoma skin lesions were included in the study. Twelve patients (24 lesions) in the experimental group received a reduced dose of BLM (10,000 IU/m2), 16 patients (28 lesions) were treated with a standard dose of BLM (15,000 IU/m2).ResultsNo statistically significant difference in tumor control was observed between both groups. In the experimental group, tumors recurred in 39.0% of treated lesions in a median follow-up time of 28 months. In the control group, the recurrence rate of treated lesions was 15.4% in a median follow-up time of 40 months.ConclusionsECT with a reduced dose of BLM is a feasible treatment option for elderly patients with equal efficacy to standard dose treatment and should be considered as a treatment modality in advanced aged patients with comorbidities, where overall life expectancy is poor.

show abstract

“…ECT is used for the treatment of cutaneous and subcutaneous tumors of different histotypes, such as skin and non-skin cancers, as well as metastases and recurrences. More recently, ECT has begun to replace thermal ablation techniques in the treatment of deep tumors [19][20][21][22][23][24][25][26][27][28][29][30][31][32]. New deployable and expandable electrode prototypes have been designed and tested for laparoscopic applications on the liver and for endoscopic trans-oral and trans-anal procedures.…”

Section: Introductionmentioning

confidence: 99%

Design and Characterization of a Minimally Invasive Bipolar Electrode for Electroporation

Merola

Fusco

Bernardo

et al. 2020

Biology

View full text Add to dashboard Cite

Objective: To test a new bipolar electrode for electroporation consisting of a single minimally invasive needle. Methods: A theoretical study was performed by using Comsol Multiphysics® software. The prototypes of electrode have been tested on potatoes and pigs, adopting an irreversible electroporation protocol. Different applied voltages and different geometries of bipolar electrode prototype have been evaluated. Results: Simulations and pre-clinical tests have shown that the volume of ablated area is mainly influenced by applied voltage, while the diameter of the electrode had a lesser impact, making the goal of minimal-invasiveness possible. The conductive pole’s length determined an increase of electroporated volume, while the insulated pole length inversely affects the electroporated volume size and shape; when the insulated pole length decreases, a more regular shape of the electric field is obtained. Moreover, the geometry of the electrode determined a different shape of the electroporated volume. A parenchymal damage in the liver of pigs due to irreversible electroporation protocol was observed. Conclusion: The minimally invasive bipolar electrode is able to treat an electroporated volume of about 10 mm in diameter by using a single-needle electrode. Moreover, the geometry and the electric characteristics can be selected to produce ellipsoidal ablation volumes.

show abstract

Electrochemotherapy of superficial tumors – Current status:

Cited by 87 publications

References 252 publications

Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome

Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome

Long term response of electrochemotherapy with reduced dose of bleomycin in elderly patients with head and neck non-melanoma skin cancer

Design and Characterization of a Minimally Invasive Bipolar Electrode for Electroporation

Contact Info

Product

Resources

About